Tscan Therapeutics Stock Probability Of Bankruptcy
| TCRX Stock | USD 1.74 0.05 2.79% |
Tscan | Probability Of Bankruptcy |
Tscan Therapeutics Company probability of bankruptcy Analysis
Tscan Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Tscan Therapeutics Probability Of Bankruptcy | Over 78% |
Most of Tscan Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tscan Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Tscan Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Tscan Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Tscan Therapeutics financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tscan Therapeutics. If investors know Tscan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tscan Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.14) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
The market value of Tscan Therapeutics is measured differently than its book value, which is the value of Tscan that is recorded on the company's balance sheet. Investors also form their own opinion of Tscan Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tscan Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tscan Therapeutics' market value can be influenced by many factors that don't directly affect Tscan Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tscan Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tscan Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tscan Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Tscan Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Tscan Therapeutics is extremely important. It helps to project a fair market value of Tscan Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Tscan Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tscan Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tscan Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Tscan Therapeutics has a Probability Of Bankruptcy of 78%. This is 80.18% higher than that of the Biotechnology sector and 42.23% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 95.83% lower than that of the firm.
Tscan Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tscan Therapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tscan Therapeutics could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics of similar companies.Tscan Therapeutics is currently under evaluation in probability of bankruptcy category among its peers.
Tscan Therapeutics Main Bankruptcy Drivers
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Net Debt | (27.4M) | (155.4M) | (34.0M) | (40.9M) | (113.4M) | (107.7M) | |
| Total Current Liabilities | 17.4M | 21.3M | 17.3M | 29.8M | 36.0M | 22.8M | |
| Non Current Liabilities Total | 74.8M | 6.0M | 82.4M | 91.5M | 94.2M | 75.7M | |
| Total Assets | 49.7M | 188.1M | 199.1M | 272.1M | 371.1M | 207.1M | |
| Total Current Assets | 36.4M | 165.7M | 120.0M | 194.2M | 292.7M | 156.1M | |
| Total Cash From Operating Activities | (3.0M) | (48.7M) | (66.5M) | (61.4M) | (110.8M) | (105.3M) |
Tscan Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (55.21) % | ||||
| Current Valuation | (94.26 M) | ||||
| Shares Outstanding | 52.31 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 90.58 % | ||||
| Number Of Shares Shorted | 2 M | ||||
| Price To Earning | 23.45 X | ||||
| Price To Book | 0.41 X | ||||
| Price To Sales | 34.97 X | ||||
| Revenue | 2.82 M | ||||
| Gross Profit | (2.03 M) | ||||
| EBITDA | (119.74 M) | ||||
| Net Income | (127.5 M) | ||||
| Cash And Equivalents | 125.6 M | ||||
| Cash Per Share | 5.22 X | ||||
| Total Debt | 65.31 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 4.26 X | ||||
| Cash Flow From Operations | (110.82 M) | ||||
| Short Ratio | 5.80 X | ||||
| Earnings Per Share | (1.14) X | ||||
| Target Price | 9.71 | ||||
| Number Of Employees | 194 | ||||
| Beta | 0.91 | ||||
| Market Capitalization | 98.47 M | ||||
| Total Asset | 371.12 M | ||||
| Retained Earnings | (375.1 M) | ||||
| Working Capital | 256.77 M | ||||
| Net Asset | 371.12 M |
About Tscan Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tscan Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tscan Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tscan Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.